Evaluation of spleen tyrosine kinase as a potential therapeutic target in treatment of early B cell acute lymphoblastic leukemia

脾酪氨酸激酶作为早期 B 细胞急性淋巴细胞白血病潜在治疗靶点的评价

• 批准号: 184705
• 负责人: Perova Tatiana
• 金额: $ 7.65万
• 依托单位: Hospital for Sick Children (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-10-01 至 2011-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=184705&lang=en
• 关键词: Acute Lymphoblastic Leukemia; B Cell Development; Flow Cytometry; Gene Expresssion Microarrays; Mouse Models; Pre-B Cell Receptor Signaling; Pre-Clinical Testing; Spleen Tyrosine Kinase; Xenotransplantation

Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer accounting for 25% of all cancer diagnosed in children. Over the past years, great progress have been made in the treatment of ALL; however, at least 25% of pediatric patients

急性淋巴细胞白血病（ALL）是最常见的儿童癌症类型，占儿童诊断的所有癌症的25%。在过去几年中，在治疗ALL方面取得了巨大进展；然而，至少25%的儿科患者